CTOs on the Move

SimBioSys Inc

www.simbiosys.ca

 
SimBioSys Inc is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.simbiosys.ca
  • 135 Queens Plate Dr
    Etobicoke, ON CAN M9W 6V1
  • Phone: 406.741.5084

Executives

Name Title Contact Details

Similar Companies

Celldex Therapeutics

Celldex Therapeutics is a Needham Heights, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merck Millipore

Merck Millipore is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BlackThorn Therapeutics

BlackThorn Therapeutics is a neurobehavioral health company developing targeted therapeutics, informed by a deep understanding of brain and behavior relationships, to significantly improve patient outcomes.

EpiVax Oncology

EpiVax Oncology is developing precision cancer immunotherapies based on mutanome-directed neo-epitopes, selected using proprietary and validated in silico predictive algorithms. Neo-epitopes are mutated and tumor specific epitopes, recognized as non-self, capable of generating highly potent specific T cell immunogenic responses against tumors, translating in improved clinical outcome. EpiVax Oncology is developing neo-epitope based therapeutic vaccines customized and specifically designed for each cancer patient, based on the genetic profiling (using next generation DNA sequencing) of each patient`s unique tumor and normal genome sequence (the mutanome). EpiVax Oncology`s ultimate purpose is to address major unmet medical needs inadequately addressed by other oncology and immuno-oncology treatments which are either only benefiting a very limited subset of patients, or prone to adverse events, or extremely costly and complex to manufacture. EpiVax Oncology`s ambition is to become a premier cancer precision medicine company, leveraging EpiVax`s world class excellence in computational-immunology, genomics and vaccine design, built over the last 20 years.

Evommune

Evommune is a clinical stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases. We are leveraging our innovative, tissue-based approach to advance insights and accelerate the development of these transformative therapies. Evommune is led by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases.